Business
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival) ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in t
About this update from Ascentage Pharma Group International
[{"type":"image","alt":"ASCENTAGE PHARMA GROUP INTERNATIONAL","displaySize":"","headline":null,"caption":"ASCENTAGE PHARMA GROUP INTERNATIONAL","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/83c243f98269a5be00d529ddda07bc2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GOf2VIvpehDsvnIO9ha4CQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/83c243f98269a5be00d529ddda07bc2b","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) ","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable safety profile with 7% vascular occlusion rate ","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival)","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":287,"olType":false},{"type":"text","content":"ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented four year follow-up data from its randomized controlled, registrational Phase II study of Olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. Building on results released in an oral presentation at ASH 2023, these data reaffirm Olverembatinib’s differentiated long-term efficacy and safety.","length":857,"tagName":"p"},{"type":"text","content":"The ASH Annual Meeting is one of the largest gatherings of the international hematology community, aggregating cutting-edge scientific research and the latest data on investigational therapies that represent leading scientific and clinical advances in the global hematology field. Once again, Ascentage Pharma’s innova...